Adagio Therapeutics, Inc. – NASDAQ:ADGI
Founder-led company
Adagio Therapeutics stock price today
$4.64
+1.15
+33.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Adagio Therapeutics stock price monthly change
+6.10%
month
Adagio Therapeutics stock price quarterly change
-12.78%
quarter
Adagio Therapeutics stock price yearly change
-81.82%
year
Adagio Therapeutics key metrics
Market Cap | 505.67M |
Enterprise value | 29.86M |
P/E | -1.76 |
EV/Sales | 9955789.86 |
EV/EBITDA | -0.10 |
Price/Sales | 167298123.2 |
Price/Book | 1.20 |
PEG ratio | 1.84 |
EPS | -3.68 |
Revenue | N/A |
EBITDA | -291.32M |
Income | -291.73M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -9724600000% |
Oper. margin | -9866533333.33% |
Gross margin | 0% |
EBIT margin | -9866533333.33% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAdagio Therapeutics stock price history
Adagio Therapeutics stock forecast
Adagio Therapeutics financial statements
| Sep 2021 | 3 | -60.37K | -2012500% |
|---|---|---|---|
| Dec 2021 | 0 | -140.02M | |
| Mar 2022 | 0 | -100.66M | |
| Jun 2022 | 0 | -50.99M |
| 2022-05-13 | -0.82 | -0.93 |
|---|---|---|
| 2022-08-15 | -0.57 | -0.47 |
| Sep 2021 | 686270000 | 53.05M | 7.73% |
|---|---|---|---|
| Dec 2021 | 616794000 | 62.07M | 10.06% |
| Mar 2022 | 556273000 | 96.88M | 17.42% |
| Jun 2022 | 484612000 | 69.77M | 14.4% |
| Sep 2021 | -54.21M | 0 | 328.6M |
|---|---|---|---|
| Dec 2021 | -106.78K | -50.71K | 334.08K |
| Mar 2022 | -59.04M | 49M | 45K |
| Jun 2022 | -57.39M | -17K | 74K |
Adagio Therapeutics alternative data
| Aug 2023 | 101 |
|---|---|
| Sep 2023 | 101 |
| Oct 2023 | 101 |
| Nov 2023 | 101 |
| Dec 2023 | 101 |
| Jan 2024 | 101 |
| Feb 2024 | 101 |
| Mar 2024 | 101 |
| Apr 2024 | 101 |
| May 2024 | 101 |
| Jun 2024 | 101 |
| Jul 2024 | 101 |
Adagio Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2022 | 2850000 | 0 |
| Sep 2022 | 8000 | 0 |
| Insider | Compensation |
|---|---|
| Dr. Rebecca Dabora Ph.D. (1959) Chief Technology & Manufacturing Officer | $622,280 |
| Ms. Lynn Connolly M.D., Ph.D. (1967) Chief Medical Officer | $430,890 |
Dr. Rene Russo BCPS, Pharm.D (1975) Co-Founder & Independent Chair of the Board | $78,340 |
-
What's the price of Adagio Therapeutics stock today?
One share of Adagio Therapeutics stock can currently be purchased for approximately $4.64.
-
When is Adagio Therapeutics's next earnings date?
Unfortunately, Adagio Therapeutics's (ADGI) next earnings date is currently unknown.
-
Does Adagio Therapeutics pay dividends?
No, Adagio Therapeutics does not pay dividends.
-
How much money does Adagio Therapeutics make?
Adagio Therapeutics has a market capitalization of 505.67M. Adagio Therapeutics made a loss 226.79M US dollars in net income (profit) last year or -$0.47 on an earnings per share basis.
-
What is Adagio Therapeutics's stock symbol?
Adagio Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ADGI".
-
What is Adagio Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Adagio Therapeutics?
Shares of Adagio Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Adagio Therapeutics's key executives?
Adagio Therapeutics's management team includes the following people:
- Dr. Rebecca Dabora Ph.D. Chief Technology & Manufacturing Officer(age: 66, pay: $622,280)
- Ms. Lynn Connolly M.D., Ph.D. Chief Medical Officer(age: 58, pay: $430,890)
- Dr. Rene Russo BCPS, Pharm.D Co-Founder & Independent Chair of the Board(age: 50, pay: $78,340)
-
Is Adagio Therapeutics founder-led company?
Yes, Adagio Therapeutics is a company led by its founder Dr. Rene Russo BCPS, Pharm.D.
-
How many employees does Adagio Therapeutics have?
As Jul 2024, Adagio Therapeutics employs 101 workers.
-
When Adagio Therapeutics went public?
Adagio Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 6 Aug 2021.
-
What is Adagio Therapeutics's official website?
The official website for Adagio Therapeutics is adagiotx.com.
-
Where are Adagio Therapeutics's headquarters?
Adagio Therapeutics is headquartered at 303 Wyman Street, Waltham, MA.
-
How can i contact Adagio Therapeutics?
Adagio Therapeutics's mailing address is 303 Wyman Street, Waltham, MA and company can be reached via phone at +60 32522274.
Adagio Therapeutics company profile:
Adagio Therapeutics, Inc.
adagiotx.comExchange:
NASDAQ
Full time employees:
101
Industry:
Biotechnology
Sector:
Healthcare
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
303 Wyman Street
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001832038
ISIN: US00534A1025
CUSIP: 00534A102
